A new survey reported by Dermatology Times finds a rise in patients on GLP-1 receptor agonists seeking cosmetic care, a demand signal aesthetic practices can no longer treat as incidental.

The survey, highlighted by Dermatology Times, points to a growing overlap between medical weight management and cosmetic dermatology. Patients taking GLP-1 medications — the drug class behind semaglutide products such as Ozempic and Wegovy, and tirzepatide products such as Mounjaro and Zepbound — are presenting in aesthetic practices in growing numbers, according to the report.

The survey itself does not introduce a new device or injectable. What it documents is a shift in who walks through the door, and why.

Why are GLP-1 patients landing in aesthetic clinics?

Rapid, large-volume weight loss changes the face as well as the body. Dermatologists and aesthetic clinicians have been reporting what the field informally calls "Ozempic face" — volume loss, skin laxity and deflation in the midface and lower face that can read as accelerated aging.

The new survey data, as covered by Dermatology Times, suggests this is no longer anecdote. Patients on GLP-1 therapy are actively seeking cosmetic consultation, and practices are adjusting what they offer and how they counsel.

That has practical implications for consult structure. A patient who has lost a significant share of body weight on a GLP-1 agonist presents differently from a patient seeking routine rejuvenation. Volume deficits may be distributed across the midface, jawline and neck rather than concentrated in one compartment, and skin quality issues — laxity above all — may dominate over rhytides.

What should practices do with the finding?

For practices, the survey's signal is a workforce and protocol question as much as a clinical one. Clinics that track why new patients book may want to add GLP-1 use to intake forms, since medication status changes the likely treatment plan: more emphasis on soft-tissue augmentation and skin-tightening devices, less on neurotoxin-first strategies alone.

Counseling matters too. Patients who lose weight rapidly often have expectations calibrated to their slimmer body, not to the deflated facial fat compartments that come with it. Setting realistic sequence and timeline — and screening for ongoing weight loss before committing to volumizing treatment — is standard practice for this cohort, and the survey's finding gives practices a reason to formalize it.

The Dermatology Times report also lands amid a broader convergence: GLP-1 prescribing has scaled rapidly across primary care, obesity medicine and endocrinology, which means dermatology and aesthetic clinics sit downstream of a much larger prescribing wave.

What comes next?

The survey frames the GLP-1 population as a durable, growing segment of cosmetic demand rather than a passing trend — and as GLP-1 use continues to expand, practices that build consultation pathways for these patients will be positioned to meet them.